ELISA Kit for Noggin (NOG) Homo sapiens (Human) Sandwich ELISA

SYM1; SYNS1; Synostoses(Multiple)Syndrome 1; Symphalangism 1(Proximal)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Noggin (NOG) Packages (Simulation)
  • ELISA Kit for Noggin (NOG) Packages (Simulation)
  • ELISA Kit for Noggin (NOG) Results demonstration
  • SEC130Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Noggin (NOG) and the recovery rates were calculated by comparing the measured value to the expected amount of Noggin (NOG) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-102 87
EDTA plasma(n=5) 89-97 94
heparin plasma(n=5) 89-103 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Noggin (NOG) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Noggin (NOG) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Noggin (NOG) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 83-98% 80-92% 78-98% 97-105%
EDTA plasma(n=5) 91-99% 93-105% 81-88% 88-98%
heparin plasma(n=5) 81-96% 83-92% 82-96% 94-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

ELISA Kit for Noggin (NOG)

Test principle

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Noggin (NOG). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Noggin (NOG). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Noggin (NOG), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Noggin (NOG) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Citations

  • Imbalance between BMP2 and Noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitisPubMed: 26413886
  • Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing SpondylitisPubmed:26413886
  • Oxygen-glucose deprivation preconditioning protects neurons against oxygen-glucose deprivation/reperfusion induced injury via bone morphogenetic protein-7 mediated ERK, p38 and Smad signalling pathways.Pubmed:26385023
  • The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells.pubmed:28266688
  • mbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal OsteogenicDifferentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis.pubmed:26413886
  • The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.pubmed:28981962
  • Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesispubmed:29167826
  • Low‐intensity pulsed ultrasound promotes bone morphogenic protein 9‐induced osteogenesis and suppresses inhibitory effects of inflammatory cytokines on cellular …Pubmed: 31006911
  • Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatmentPubmed: 32160825
  • Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat Epigastric Free Flap ModelPubmed: 31995818
  • Slow diffusion on the monolayer culture enhances auto/paracrine effects of Noggin in differentiation of human iPS cells induced by BMPPubmed:35005256

Recommend products